The U.S. next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and region. The product type segment includes inhalable insulin, oral insulin, insulin patch, continuous glucose monitoring systems (CGMS), and artificial pancreas. Based on demographic, the market is bifurcated into adult population (>14years) and child population (=14years). Based on indication, the market is divided into diabetes I and II. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare.
Rise in the number of diabetic cases and the benefits of using these advanced devices over conventional products boost the market growth. The well-established healthcare infrastructure and high R&D activities for the advancement in diabetes therapeutic technology are expected to provide opportunities for market growth. However, less variability in products and cost restraints among low and middle-income population are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients in the U.S. are projected to help to open new doors for the growth of the next generation diabetes therapy and drug delivery market.
KEY MARKET BENEFITS
- This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
- The market estimations provided are based on comprehensive analysis of the key developments in the industry.
- The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indications, and end user.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
By Product Type
- Inhalable Insulin
- Oral Insulin
- Insulin Patch
- CGM System
- Artificial Pancreas
- Adult Population (>14 years)
- Child Population (=14 years)
- Home Healthcare
- Abbott Laboratories
- Echo Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- GlySens Incorporated
- Medtronic Plc
- Novo Nordisk
- MannKind Corporation
- Dexcom, Inc.
- Senseonics Holding, Inc.
- Zosano Pharma Corp.
- Relmada Therapeutics, Inc.
- Eli Lilly and Company
- Enteris BioPharma
- Transdermal Specialties Inc.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. KEY BENEFITS
3.1.1. Top investment pockets
3.1.2. Top winning strategies
3.2. PATENT ANALYSIS
3.2.1. Patent analysis by year
3.2.2. Patent analysis by product
3.3. GOVERNMENT REGULATIONS
3.3.1. U.S. FDA
3.4. REIMBURSEMENT POLICIES
3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET
3.5.1. Smart contact lenses for glucose monitoring
3.5.2. iLet bihormonal bionic pancreas
3.5.3. Glucose nanosensors
3.5.4. Beta cell replacement therapy
3.5.5. Glucose-responsive insulin-producing cells
3.6. MARKET DYNAMICS
126.96.36.199. Rise in incidence of diabetes
188.8.131.52. Rise in healthcare expenditure & disposable income
184.108.40.206. Benefits of using next generation diabetes products over conventional products
220.127.116.11. Cost restrains
18.104.22.168. Lack of awareness
22.214.171.124. Less variability in products
126.96.36.199. Developing products with fewer side effects at affordable costs
188.8.131.52. High undiagnosed diabetic patient population
CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT
4.1.1. Market size and forecast
4.2. INHALABLE INSULIN
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. ORAL INSULIN
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. INSULIN PATCHES
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.6. ARTIFICIAL PANCREAS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS
5.1.1. Market size and forecast
5.2. ADULT POPULATION (>14YEARS)
5.2.1. Market size and forecast
5.3. CHILD POPULATION (14YEARS)
5.3.1. Market size and forecast
CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION
6.1.1. Market size and forecast
6.2. TYPE I DIABETES
6.2.1. Market size and forecast
6.3. TYPE II DIABETES
6.3.1. Market size and forecast
CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER
7.1.1. Market size and forecast
7.2.1. Market size and forecast
7.3. INTENSIVE CARE UNITS (ICU)
7.3.1. Market size and forecast
7.4. HOME HEALTHCARE
7.4.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. DEXCOM, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. ECHO THERAPEUTICS, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. F. HOFFMANN-LA ROCHE LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GLYSENS INCORPORATED
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product portfolio
8.5.4. Key strategic moves and developments
8.6. MANNKIND CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. NOVO NORDISK A/S
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. SENSEONICS HOLDINGS, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
Next generation diabetes therapy and drug delivery devices are the advanced form of diabetic products that help improve the quality of life of diabetic patients. Oral and inhalable insulin introduces a different mode of insulin delivery in diabetic patients. As compared to injectable insulins, oral and inhalable insulin are painless mode of introducing insulin and reduces the risk of skin irritation due to needles. With the advancements in diabetes therapy systems such as insulin patches, CGM systems, and artificial pancreas, these devices can frequently detect the glucose levels and adjust the insulin levels that need to be used to manage the variation in glucose levels.
The market is expected to witness an exponential growth during the forecast period due to the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure. Moreover, the availability of high disposable income and technological advancement of next generation diabetic products help fuel the market growth. However, cost restraints among the low and middle income population and less variability in products are expected to hinder the growth.
As compared to other diabetic products, CGM system is a well-established market and dominates the next generation diabetes therapy and drug delivery market. This is attributed to the presence of a large patient base suffering from diabetes and advantages of using these systems as compared to conventional diabetic products such as ease of usage, and efficient and early detection of change in blood glucose levels.
Among the end users, diagnostics/clinics is the largest contributor toward the market and is anticipated to continue its dominance during the analysis period. This is due to the increase in procurement of the products from diagnostics and clinics by diabetic patients.
Depending on demographics, the market is bifurcated into adult and child population. Adult population is the dominant segment that contributes toward the market growth as almost 90% of the diabetic population in the U.S. is above the age of 18 years.
Key findings of the U.s. Next Generation Diabetes Therapy And Drug Delivery Market:
The home healthcare segment is projected to grow at the highest rate during the analysis period.
CGM system was the highest revenue contributor, and is expected to continue its dominance throughout the forecast period.
Diagnostics/clinics dominated the U.S. next generation diabetes therapy and drug delivery market, and is projected to grow at a CAGR of 32.0%.
Type II diabetes is the fastest growing segment in the U.S., registering a CAGR of 33.1%.
The major companies profiled in the report include Abbott Laboratories, Echo Therapeutics, Inc., F. Hoffmann-La Roche Ltd., GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannKind Corporation, Dexcom, Inc., and Senseonics Holding, Inc.
Other players in the value chain include Enteris BioPharma, Synertech, Zosano Pharma Corp., Relmada Therapeutics, Inc., Eli Lilly and Company, and Transdermal Specialties Inc.